Molecular Subtype
Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive
CI-CAN-00004952Explore in graph →
Hematologic6 active trials1 approved drugs
- NCIt
- C9128
Loading cancer entity…
Molecular Subtype
CI-CAN-00004952Explore in graph →
Clinical trials
14 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01746836 | Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
Data updated 14 days agoSource updated Sep 16, 2026source: clinicaltrials